GENERIC AVAILABLE: No
PREPARATIONS: Injection Concentrate: 20 mg/0.5 ml, 80 mg/2 ml; Injection (Powder): 20 mg/vial, 80 mg/vial
STORAGE: Docetaxel concentrate should be stored between 2 C and 25 C (36 F to 77 F), and the powder should be stored between 2 C and 8 C (36 F and 46 F). They should be retained in their original package to protect them from light.
DOSING: Docetaxel is given intravenously. Doses range from 60 mg/m2 to 100 mg/m2 every 3 weeks in combination with other chemotherapy agents. Dexamethasone also is administered prior to docetaxel to reduce the severity of fluid retention and occurrence of hypersensitivity reactions.
DRUG INTERACTIONS: Drugs that reduce the activity of liver enzymes that break down docetaxel and other drugs increase the blood levels of docetaxel and increase its side effects. Examples include ketoconazole (Nizoral, Extina, Xolegel, Kuric), erythromycin (E-Mycin, Eryc, Ery-Tab, Pce, Pediazole, Ilosone), and protease inhibitors (for example, ritonavir [Norvir]).
PREGNANCY: Docetaxel can cause fetal harm when administered to pregnant women. Women of childbearing potential should use an adequate form of contraception and should be advised not to become pregnant during therapy with docetaxel.
NURSING MOTHERS: It is not known whether docetaxel is excreted in human milk. Because of the risk for serious adverse reactions in nursing infants, mothers should discontinue nursing prior to taking docetaxel.
Medically reviewed by Eni Williams, PharmD
Reference: FDA Prescribing Information
Quick GuideBreast Cancer Diagnosis and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.